KPV is the C-terminal tripeptide (Lysine-Proline-Valine) of alpha-melanocyte-stimulating hormone (α-MSH) — the three-amino acid sequence that contains the full anti-inflammatory activity of the parent hormone without its melanocyte-stimulating effects. This minimal bioactive fragment has been particularly well-characterized for gastrointestinal inflammation, where it functions as a potent, locally-acting anti-inflammatory through multiple converging mechanisms.

Alpha-MSH and Its Fragments

Alpha-MSH is a 13-amino acid peptide derived from proopiomelanocortin (POMC) that acts on all five melanocortin receptors (MC1R–MC5R). While MC1R activation by α-MSH drives melanin production and tanning, the molecule also has potent anti-inflammatory effects mediated primarily through MC3R and MC4R on immune cells, epithelial cells, and neurons.

KPV corresponds to α-MSH 11–13 — the C-terminal tripeptide. Research by Catania and colleagues established that this tripeptide fragment retains the anti-inflammatory and anti-nociceptive properties of full α-MSH with minimal melanocyte-stimulating activity. Because KPV is only 3 amino acids, it is also highly stable in biological fluids and can remain active after oral administration where larger peptides might be degraded.

Mechanism: Multi-Target Anti-Inflammation

KPV reduces inflammation through multiple pathways: 1. NF-κB inhibition: KPV suppresses nuclear factor-κB (NF-κB) activation — the master transcriptional regulator of inflammatory cytokine production. Reduced NF-κB translocation decreases IL-6, TNF-α, IL-1β, and MCP-1 expression in intestinal epithelial cells and immune cells. 2. MAPK pathway modulation: Inhibits ERK1/2 and p38 MAPK signaling — two inflammatory kinase cascades activated by cytokines and pathogen-associated molecular patterns. 3. Direct cellular penetration: KPV can penetrate intestinal epithelial cells directly and act intracellularly on NF-κB pathways — a mechanism not dependent on surface receptor engagement. 4. JAK/STAT3 pathway modulation: KPV reduces STAT3 phosphorylation, an important driver of inflammatory gene expression in intestinal epithelial cells.

Gastrointestinal Applications

KPV's most studied applications involve GI inflammation:

• **Inflammatory Bowel Disease (IBD)**: Murine models of Crohn's disease and ulcerative colitis show oral KPV significantly reduces colonic inflammation markers, maintains epithelial barrier function, and preserves normal mucosal architecture. Critically, these effects are achieved without systemic immunosuppression — KPV acts locally within the GI tract.

• **Gut Epithelial Barrier Protection**: KPV preserves and restores tight junction integrity, reducing intestinal permeability (leaky gut). This barrier-protective effect works alongside BPC-157 through complementary mechanisms.

• **Post-Inflammatory Mucosal Repair**: Following acute GI inflammation (from infection, NSAIDs, alcohol, stress), KPV accelerates mucosal recovery by reducing residual inflammation and promoting epithelial cell survival.

Systemic Applications

Beyond the GI tract, KPV shows anti-inflammatory effects in: - Skin inflammation models (eczema, dermatitis) - Neurological inflammation (neuroprotective effects in inflammatory models) - Wound healing acceleration through reduced inflammatory phase